Ligand Pharmaceuticals will pay $23 million upfront for 100% of certain Royalty and milestone rights tied to Santen’s Ryjunea in Europe, the Middle East and Africa. The deal matters to investors because Ligand will receive tiered low-double-digit to high-teens royalties on Ryjunea net sales in those territories, plus certain milestone payments.

Key Highlights

  • Ryjunea has European Commission and UK MHRA approval as a pharmacological treatment intended to slow myopia progression in pediatric patients.
  • Ryjunea uses a standardized 0.01% atropine formulation with deuterated water.
  • Sydnexis retains Ryjunea commercial rights in the United States and territories outside those licensed to Santen.

$23 Million Purchase Covers Ryjunea Payment Rights

LIGAND PHARMACEUTICALS INC (NASDAQ: LGND) is a Pharmaceuticals: Major company. Certain milestone payments are included as well. Sydnexis keeps Ryjunea commercial rights in the United States and in territories outside those licensed to Santen. Santen obtained its EMEA rights from Sydnexis in 2021, while Ligand’s acquired interest covers payments under that arrangement. The product uses a standardized 0.01% atropine formulation with deuterated water, which the release says was designed to improve efficacy, comfort and stability for pediatric use. Ligand also expects certain reimbursement approval and sales milestones connected with Ryjunea.